Edoxaban: Impact on routine and specific coagulation assays: A practical laboratory guide

Thrombosis and Haemostasis

Volumn 115, Issue 2, 2016, Pages 368-381

  Douxfils, Jonathan ^a   Chatelain, Bernard ^b   Chatelain, Christian ^b   Dogné, Jean Michel ^a   Mullier, François ^a,b  

^a University of Namur   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Coagulation tests; Drug measurement; Edoxaban; Factor Xa inhibitors; Guidelines

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; EDOXABAN; FIBRINOGEN; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ACTIVATED PROTEIN C RESISTANCE ASSAY; ARTICLE; ASSAY; BLEEDING; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; ECARIN CLOTTING TIME ASSAY; EXTRINSIC CLOTTING FACTOR ASSAY; FIBRINOGEN CLAUSS ASSAY; FREE PROTEIN S ANTIGEN ASSAY; HEMOSTASIS; HUMAN; INTRINSIC CLOTTING FACTOR ASSAY; LUPUS ANTICOAGULANT ASSAY; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN C ASSAY; PROTEIN S ASSAY; PROTHROMBIN TIME; REPTILASE TIME ASSAY; THROMBIN GENERATION ASSAY; THROMBIN TIME; THROMBOCYTE POOR PLASMA; THROMBOPHILIA; BLOOD; BLOOD CLOTTING; CALIBRATION; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; PLASMA; PROCEDURES; SENSITIVITY AND SPECIFICITY; THERMOGRAVIMETRY; THROMBOCYTE;

ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CALIBRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FACTOR XA INHIBITORS; FIBRINOGEN; HEMOSTASIS; HUMANS; LUPUS COAGULATION INHIBITOR; PARTIAL THROMBOPLASTIN TIME; PLASMA; PROTEIN C; PROTEIN S; PROTHROMBIN TIME; PYRIDINES; SENSITIVITY AND SPECIFICITY; THERMOGRAVIMETRY; THIAZOLES; THROMBIN; THROMBOPHILIA;

EID: 84957585824     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-05-0415     Document Type: Article

References (54)

1. Enden T, Haig Y, Klow NE, et al. Long-term outcome after additional catheterdirected thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379: 31–38.
2. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698–707.
3. Galanaud JP, Holcroft CA, Rodger MA, et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. J Thromb Haemost 2013; 11: 474–480.
4. Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009; 145: 286–295.
5. Kahn SR, Shbaklo H, Lamping DL,et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 2008; 6: 1105–1112.
6. Bergan JJ, Schmid-Schonbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med 2006; 355: 488–498.
7. Chitsike RS, Rodger MA, Kovacs MJ, et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemost 2012; 10: 2039–2044.
8. Kahn SR, Partsch H, Vedantham S, et al, Subcommittee on Control of Anticoagulation of the S, Standardisation Committee of the International Society on T, Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardisation. J Thromb Haemost 2009; 7: 879–883.
9. Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40: 1248–1252.
10. Kahn SR, Desmarais S, Ducruet T, et al. Comparison of the Villalta and Ginsberg clinical scales to diagnose the post-thrombotic syndrome: correlation with patient-reported disease burden and venous valvular reflux. J Thromb Haemost 2006; 4: 907–908.
11. Wik HS, Jacobsen AF, Sandvik L, Sandset PM. Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. J Thromb Haemost 2012; 10: 840–847.
12. Villalta S, Bagatella P, Piccioli A, Lensing A, Prins M, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis 1994; 24: 158a.
13. Ware JE KM, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User’s Manual. New England Medical Centre, Boston: 1994.
14. McHugh ML. Interrater reliability: the kappa statistic. Biochem Medica 2012; 22: 276–282.
15. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent postthrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383: 880–888.
16. Galanaud JP, Holcroft CA, Rodger MA, et al. Comparison of the Villalta postthrombotic syndrome score in the ipsilateral vs. contralateral leg after a first unprovoked deep vein thrombosis. J Thromb Haemost 2012; 10: 1036–1042.
17. Soosainathan A, Moore HM, Gohel MS, Davies AH. Scoring systems for the post-thrombotic syndrome. J Vasc Surg 2013; 57: 254–261.
18. Hull RD, Liang J, Merali T. Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac/noniliac venous thrombosis: a subanalysis from the home-LITE study. Clin Appl Thromb Hemost 2013; 19: 476–481.
19. Hull R, Butcher P. Value of patient self-assessment in the diagnosis and monitoring of post-thrombotic syndrome: the Patient-Tracked Symptoms questionnaire. Clin Appl Thromb Hemost 2012; 18: 345–350.
20. Kahn SR. The post-thrombotic syndrome: progress and pitfalls. Br J Haematol 2006; 134: 357–365. satfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf. Accessed May 5, 2015.
21. Mani H, Hesse C, Stratmann G, et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106: 156–164.
22. Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457–465.
23. Food and Drug Administration. Savaysa–Clinical Pharmacology and Biopharmaceutics Review(s). Available at. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000ClinPharmR.pdf Accessed June 12, 2015.
24. Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombol 2015; 39: 288–294.
25. Douxfils J, Dogne JM, Mullier F, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543–549.
26. Douxfils J, Tamigniau A, Chatelain B, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723–731.
27. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493–1502.
28. Francart SJ, Hawes EM, Deal AM, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 2014; 111: 1133–1140.
29. Gosselin RC, Adcock Funk DM, Taylor JM, et al. Comparison of anti-xa and dilute russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med 2014; 138: 1680–1684.
30. Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metabol Disposit 2012; 40: 2250–2255.
31. Van Blerk M, Bailleul E, Chatelain B, et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 2015; 113: 154–164.
32. Gouin-Thibault I, Flaujac C, Delavenne X, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014; 111: 240–248.
33. Samama MM, Contant G, Spiro TE, et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012; 18: 150–158.
34. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379–387.
35. Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129: 492–498.
36. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756–760.
37. Douxfils J, Tamigniau A, Chatelain B, et al. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J 2014; 12: 24.
38. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6: 1542–1549.
39. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007; 98: 883–888.
40. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263–1271.
41. Harenberg J, Kramer R, Giese C, et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombol 2011; 32: 267–271.
42. Samama MM, Amiral J, Guinet C, et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104: 1078–1079.
43. Douxfils J, Lessire S, Dincq AS, et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 2015; 113: 862–869.
44. Gerotziafas GT, Baccouche H, Sassi M, et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 2012; 129: 101–103.
45. van Os GM, de Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011; 9: 1657–1659.
46. Robert S, Ghiotto J, Pirotte B, et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 2009; 59: 160–166.
47. Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 2015; 143: 241–247.
48. Perrin J, Depasse F, Lecompte T, et al. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. Thromb Res 2015; 136: 125–130.
49. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217–224.
50. Honickel M, Treutler S, van Ryn J, et al. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 2015; 113: 728–740.
51. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113: 931–942.
52. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PloS one 2013; 8: e78696.
53. Martin AC, Gouin-Thibault I, Siguret V, et al. Multimodal assessment of nonspecific hemostatic agents for apixaban reversal. J Thromb Haemost 2015; Epub ahead of print.
54. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–1579.